178 related articles for article (PubMed ID: 8630896)
1. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
2. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Adachi T; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Arch Pathol Lab Med; 2002 Sep; 126(9):1071-8. PubMed ID: 12204056
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
5. Analysis of germline and tumor mutations of p53 gene in familial occurrence of soft tissue sarcomas.
Kudawara I; Matsumine A; Ohzono K
J Surg Oncol; 2007 Mar; 95(4):347-50. PubMed ID: 17192950
[TBL] [Abstract][Full Text] [Related]
6. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
7. No correlation of c-myc overexpression and p53 mutations in liposarcomas.
Schneider-Stock R; Walter H; Rys J; Radig K; Hoang-Vu C; Roessner A
Virchows Arch; 1998 Oct; 433(4):315-21. PubMed ID: 9808433
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
9. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach FS; Tokino T; Meltzer P; Burrell M; Oliner JD; Smith S; Hill DE; Sidransky D; Kinzler KW; Vogelstein B
Cancer Res; 1993 May; 53(10 Suppl):2231-4. PubMed ID: 8387391
[TBL] [Abstract][Full Text] [Related]
10. H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis.
Sakamoto A; Oda Y; Adachi T; Tamiya S; Matsuda S; Tanaka K; Iwamoto Y; Tsuneyoshi M
Am J Clin Pathol; 2001 Feb; 115(2):235-42. PubMed ID: 11211612
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
13. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma.
Reid AH; Tsai MM; Venzon DJ; Wright CF; Lack EE; O'Leary TJ
Diagn Mol Pathol; 1996 Mar; 5(1):65-73. PubMed ID: 8919547
[TBL] [Abstract][Full Text] [Related]
14. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances.
Idbaih A; Coindre JM; Derré J; Mariani O; Terrier P; Ranchère D; Mairal A; Aurias A
Lab Invest; 2005 Feb; 85(2):176-81. PubMed ID: 15702084
[TBL] [Abstract][Full Text] [Related]
15. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts.
Oda Y; Tamiya S; Oshiro Y; Hachitanda Y; Kinukawa N; Iwamoto Y; Tsuneyoshi M
Pathol Int; 2002 Sep; 52(9):595-606. PubMed ID: 12406189
[TBL] [Abstract][Full Text] [Related]
16. Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma.
Szollosi Z; Nemeth T; Egervari K; Nemes Z
Pathol Res Pract; 2005; 201(5):369-77. PubMed ID: 16047946
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.
Schneider-Stock R; Radig K; Oda Y; Mellin W; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(4):211-8. PubMed ID: 9177493
[TBL] [Abstract][Full Text] [Related]
18. Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas.
Oda Y; Schneider-Stock R; Ryś J; Gruchała A; Niezabitowski A; Roessner A
Diagn Mol Pathol; 1996 Jun; 5(2):98-106. PubMed ID: 8727096
[TBL] [Abstract][Full Text] [Related]
19. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours.
Soini Y; Vähäkangas K; Nuorva K; Kamel D; Lane DP; Pääkkö P
J Pathol; 1992 Sep; 168(1):29-33. PubMed ID: 1333524
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
